AlphAIAlphAI — Financial news for AI agents
investing.comOCT 212 min read$ISRG

Truist reiterates Buy on Intuitive Surgical stock, $510 target

Truist reiterated a Buy rating and $510 target on Intuitive Surgical (ISRG), citing strong capital demand and 40% net da Vinci placements growth in Q3. ISRG reported Q3 revenue of $3.05B, beating estimates, with 20.7% revenue growth over the last year. Analysts' price targets range from $400 to $550.

Original reporting
investing.com
Published Oct 21, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ISRG
Bullish
high confidence
Mentioned
$ISRG
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ISRGBullishHigh
01

Why it matters

Earnings beat and upgraded guidance are likely to drive short‑term price appreciation, though settlement costs and mixed outlooks from some analysts introduce downside risk.

02

Market read

Strong earnings and analyst upgrades make ISRG a near‑term bullish play within the healthcare sector.

03

What to watch

Potential headwinds from regulatory scrutiny of surgical robotics and competitive pressure from emerging rivals.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

The article summarizes Intuitive Surgical's third‑quarter earnings, analyst reactions, and updated price targets.

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Intuitive Surgical reported Q3 revenue of $3.05B beating estimates and GAAP EPS of $1.49, prompting multiple analyst upgrades and a $510 price target reiteration.

Expected impact

potential upside as the market prices in the earnings beat and upgraded targets

Evidence & confidence

Revenue and EPS beat, coupled with higher guidance and analyst upgrades, create a bullish catalyst.

Market effects

Sector

Positive for the medical‑device sector as Intuitive Surgical's growth underscores demand for robotic surgery platforms.

Regional

U.S. healthcare equities may see modest gains on the back of the beat.

Global

Limited to investors tracking global med‑tech leaders.

Counterpoint

What could challenge this read

The $450M litigation settlement and slower procedure growth noted by Mizuho could temper upside.

Key entities

  • company
    Intuitive Surgical

    Medical‑device maker specializing in robotic surgery systems.

  • analyst
    Truist Securities

    Reiterated Buy rating with $510 price target.

Read at source← All news

StoryIntuitive Surgical Q3 2026 earnings beat estimates but shares tumble on $450 M settlement and pricing cuts

Also covered by

3 outlets

Related articles

OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Drops as $450 Million Charge Overshadows Beat

Intuitive Surgical (ISRG) reported Q3 revenue of $3.05B, up 22%, and adjusted earnings of $3.00 per share, beating expectations. However, shares fell due to a $450M antitrust settlement and a cautious growth outlook. GAAP earnings dropped to $1.49 per share, affected by the settlement. The company placed 546 da Vinci systems, with 315 being the newer da Vinci 5 platform.

finance.yahoo.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive’s shares fall 8% after tempering 2026 procedural growth outlook

Intuitive Surgical reported Q3 revenue of $3.01B, up 22% YoY, but shares fell 8% after lowering its 2026 robotic surgery procedure growth outlook to 14-15% from 13.5-15.5%. The company cited US and Chinese market headwinds. Q3 procedures grew 15% YoY, with 546 da Vinci robots placed. CEO Dave Rosa highlighted strong performance across platforms, including FDA clearance for da Vinci 5 in March 2024.

finance.yahoo.com2 min
OCT 21
$ISRGMed

Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported strong Q3 2026 results, with da Vinci system placements up 28% globally. Da Vinci 5 and SP systems accounted for 65% of placements, and the company announced plans for a new manufacturing facility in Malaysia. ISRG also received several regulatory clearances and expects further reimbursement actions for Ion outside the U.S. The company settled a class action lawsuit related to third-party servicing of da Vinci systems.

finance.yahoo.com2 min
OCT 21
$ISRGMedAI 8/10

Stifel reiterates Intuitive Surgical stock rating after Q3 beat

Stifel maintained its Buy rating and $550 target on Intuitive Surgical (ISRG) after Q3 2026 results beat estimates. Revenue grew 20.66% YoY, with procedure growth of 10% in the U.S. and 20% internationally. Analysts have mixed views on the stock, with targets ranging from $400 to $500. Management expects strategic initiatives to boost growth.

investing.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Stock Falls Despite da Vinci 5 Placements Jump

Intuitive Surgical (ISRG) reported Q3 non-GAAP EPS of $3.00, beating estimates, on revenue of $3.05B, also exceeding expectations. GAAP EPS fell due to a $450M litigation charge. Shares dropped 7.76% premarket. Revenue rose 22%, driven by procedure growth and higher lease revenue. Da Vinci system placements increased to 546 from 427 a year earlier, with 315 being the new da Vinci 5 model.

finance.yahoo.com2 min